5/2/2014 9:39:23 AM
Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the company will deliver three posters featuring ETC-1002 Phase 2 clinical results at the 2014 Annual Scientific Sessions of the National Lipid Association in Orlando, Fla. The posters provide additional information from previously-presented Phase 2 studies of ETC-1002, and new analyses regarding blood pressure lowering in patients with both hypercholesterolemia and mildly elevated blood pressure.
Help employers find you! Check out all the jobs and post your resume.
comments powered by